What is the Impact Factor of Human Gene Therapy?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Human Gene Therapy is 4.60, ranking in quartile Q2 of Web of Science (SCIE).

Is Human Gene Therapy indexed in Web of Science or Scopus?

Yes, Human Gene Therapy is indexed in Web of Science (SCIE, Q2 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 1.282 (Q1) and an H-index of 167.

Who publishes Human Gene Therapy and what is the Article Processing Charge (APC)?

Human Gene Therapy is published by Mary Ann Liebert Inc.. The estimated Article Processing Charge (APC) is approximately $3,413 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Human Gene Therapy?

The official ISO-4 abbreviation of Human Gene Therapy is "HUM. GENE THER". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q2Scopus Q1SCImago #3,229Hybrid

Human Gene Therapy

Abbreviation (ISO):HUM. GENE THER

•

Identifier (ISSN):1043-0342(Print)/1557-7422(Online)

•

Publisher:Mary Ann Liebert Inc.

Official Website Submission Portal Compare

Clarivate IF (2026)

4.6↑ +0.6

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Human Gene Therapy

WoS Q2

Annual Impact Factor Metric

Current (2026):4.6

Scopus SJR & RankScopus Q1

1.282

#3,229

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

167

167 papers with at least that number of citations each

WoS: SCIE / JCRQ2

Self-Citation Rate7.7%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

104articles/year

16.54% Gold OA•97.96% Original Research

Aims & Scope

Human Gene Therapy is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes in-depth coverage of DNA, RNA, and cell therapies by delivering the latest breakthroughs in research and technologies. Human Gene Therapy provides a central forum for scientific and clinical information, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.

Topics Covered (Recognized by AI)

Biology94.1%Genetics90.3%Medicine87.8%Chemistry87.4%Biochemistry86.8%Gene80.3%Internal medicine53.6%Genetic enhancement50.8%Immunology47.7%Recombinant DNA40.9%Virology37%Molecular biology31.3%Cell culture28.1%Cell biology26.9%Pathology26.1%Cancer research25.8%Viral vector23.9%Virus23%

Primary Research Areas

Medicine Biotechnology & Applied Microbiology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Rank54/180

IndexSCIE

JCRSCIE2026

GENETICS & HEREDITY

Rank38/192

IndexSCIE

JCRSCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Rank58/191

IndexSCIE

JCISCIE2026

BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Rank50/180

IndexSCIE

JCISCIE2026

GENETICS & HEREDITY

Rank57/192

IndexSCIE

JCISCIE2026

MEDICINE, RESEARCH & EXPERIMENTAL

Rank57/191

IndexSCIE

Category	Index	Rank	Quartile
BIOTECHNOLOGY & APPLIED MICROBIOLOGY	JCRSCIE	54/180	Q2
GENETICS & HEREDITY	JCRSCIE	38/192	Q1
MEDICINE, RESEARCH & EXPERIMENTAL	JCRSCIE	58/191	Q2
BIOTECHNOLOGY & APPLIED MICROBIOLOGY	JCISCIE	50/180	Q2
GENETICS & HEREDITY	JCISCIE	57/192	Q2
MEDICINE, RESEARCH & EXPERIMENTAL	JCISCIE	57/191	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF4.6

Articles / Year95

Total Citations17

2025

IF4

Articles / Year106

Total Citations286

2024

IF3.9

Articles / Year84

Total Citations791

2023

IF4.2

Articles / Year133

Total Citations1,346

2022

IF4.793

Articles / Year125

Total Citations1,644

Year	Impact Factor	Articles / Year	Total Citations
2026	4.6	95	17
2025	4	106	286
2024	3.9	84	791
2023	4.2	133	1,346
2022	4.793	125	1,644
2021	5.695	153	2,118
2020	4.273	179	3,852
2019	3.855	120	3,085
2018	4.241	159	5,969
2017	—	151	5,248
2016	—	135	4,216
2015	—	116	4,427

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #3,229Scopus Q1SCImago Profile

Scopus Coverage:1990-2026

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular Biology

Scopus Citation Rank (SJR)Q1

1.282

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

3.78

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,413 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,237

3-Year Documents341

Citable Documents318

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate46.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

GeneticsQ1

Molecular BiologyQ2

Molecular MedicineQ2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 7.7%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区BIOTECHNOLOGY & APPLIED MICROBIOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Human Gene Therapy (abbr: HUM. GENE THER, ISSN: 1043-0342) is a peer-reviewed international scholarly journal in the field of Medicine, published by Mary Ann Liebert Inc. in United States since 1990. The periodical holds a Journal Impact Factor (JIF) of 4.60, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 1.282 (Q1), an H-index of 167.

The journal enforces rigorous peer evaluation with a publication frequency of Semimonthly, an annual output of approximately 104 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,413 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.